1. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5:559–78. [PubMed]
2. Patrick DL, Erickson P. New York, NY: Oxford University Press; 1993. Health Status and Health Policy.
3. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. New York, NY: Oxford University Press; 1996. Cost-Effectiveness in Health and Medicine: Report of the Panel on Cost-Effectiveness in Health and Medicine.
4. Gold MR, Patrick DL, Torrance GW, et al. Cost-Effectiveness in Health and Medicine: Report of the Panel on Cost-Effectiveness in Health and Medicine. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. New York, NY: Oxford University Press; 1996. Identifying and valuing outcomes.
5. Luce BR, Manning WG, Siegel JE, Lipscomb J. Cost-Effectiveness in Health and Medicine: Report of the Panel on Cost-Effectiveness in Health and Medicine. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. New York, NY: Oxford University Press; 1996. Estimating costs in cost-effectiveness analysis.
6. Park RE, Fink A, Brook RH, et al. Physician ratings of appropriate indicators for six medical and surgical procedures. Am J Public Health. 1986;76:766–72. [PubMed] 7. Leape LL. Practice guidelines and standards: an overview. Qual Rev Bull. 1990;16(9):42–9. [PubMed]
8. Leape LL, Brook RH. RAND Corporation Appropriateness Rating Program: Context and Purpose. Paper presented at Workshop to Improve Group Judgement for Medical Practice and Technology Assessment sponsored by the Council of Health Care Technology, Division of Health Care Services, Institute of Medicine, Washington, DC, May 15–16, 1990.
9. Kuntz KM, Weinstein MC. Life expectancy biases in clinical decision modeling. Med Decis Making. 1995;15:158–169. [PubMed]
10. Russell LR, Taylor WC, Jagannathan R, Milan E. What statistical model best describes heart disease risk? Evidence from the NHANES I epidemiologic follow-up study. In: The Risk and Risk Factor Modeling Project: Final Report. Washington, DC: Agency for Health Care Policy and Research, U.S. Public Health Service; 1995. Grant HS 07002.
11. Fryback DG. Bayes’ theorem and conditional non-independence of data in medical diagnosis. Comput Biomed Res. 1978;11:423–34. [PubMed] 12. Poses RM, Cebul RD, Centor RM. Evaluating physicians’ probabilistic judgments. Med Decis Making. 1988;8:233–40. [PubMed] 13. Ellenberg JH. Selection bias in observational and experimental studies. Stat Med. 1994;13(9):557–67. [PubMed] 14. Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983;39:207–15. [PubMed]
15. U.S. Preventive Services Task Force (USPSTF) 2d ed. Baltimore, Md: Williams and Wilkins; 1995. Guide to Clinical Preventive Services.
16. Mandelblatt JS, Fryback DG, Weinstein MC, Russell LB, Gold MR, Hadorn DC. Cost-Effectiveness in Health and Medicine: Report of the Panel on Cost-Effectiveness in Health and Medicine. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. New York, NY: Oxford University Press; 1996. Assessing the effectiveness of health interventions. In.
17. Weiss NS. Control definition in case-control studies of the efficacy of screening and diagnostic testing. Am J Epidemiol. 1983;116:457–60. [PubMed] 18. Morrison AS. Case definition in case-control studies of the efficacy of screening. Am J Epidemiol. 1982;115:6–8. [PubMed] 19. Conner RJ, Prorok PC, Weed DL. The case-control design and the assessment of the efficacy of cancer screening. J Clin Epidemiol. 1991;44:1215–21. [PubMed] 20. Gill TM, Horwitz RI. Evaluating the efficacy of cancer screening: clinical distinctions and case-control studies. J Clin Epidemiol. 1995;48:281–92. [PubMed] 21. Selby JV, Friedman GD, Weiss NS. Case-control evaluation of screening. J Clin Epidemiol. 1996;49:390–1. Letter. [PubMed] 22. Selby JV. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653–7. [PubMed]
23. Mosteller F. Washington, DC: National Academy Press; 1985. Assessing Medical Technologies. Institute of Medicine, Committee for Evaluating Medical Technologies in Clinical Use.
24. Mitchell JB, Bubolz T, Paul JE, et al. Using medicare claims for outcomes research. Med Care. 1994;32(9):JS38–51. [PubMed]
25. Massey JT, Moore TF, Parsons VL, Tadros W. Design and estimation for the National Health Interview Survey, 1985–94. Vital Health Stat. 1989;2:110.
26. Ezzati TM, Massey JT, Waksberg J, Chu A, Maurer KR. Sample design: Third National Health and Nutrition Examination Survey. Vital Health Stat 2. 1992;113:1–35. [PubMed] 27. Ingram DD, Makuc DM. Statistical issues in analyzing the NHANES I epidemiologic follow up study. Vital Health Stat 2. 1994;121:1–30. [PubMed] 28. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev. 1992;14:154–76. [PubMed] 29. Hasselblad V, McCrory DC. Meta-analytic tools for medical decision making: a practical guide. Med Decis Making. 1995;15:81–96. [PubMed] 30. Sacks HS, Berrier J, Teitman D, Ancona-Berk VA, Chalmer TC. Meta-analysis of randomized controlled trials. N Engl J Med. 1987;316:450–5. [PubMed] 31. L’Abbe KA, Detsky AS, O’Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224–33. [PubMed]
32. Petitti DB. New York, NY: Oxford University Press; 1994. Meta-analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine.
33. Eddy DM, Hasselblad V, Schachter R. Boston, Mass: Academic Press; 1992. Meta-analysis by the Confidence Profile Method: The Statistical Synthesis of Evidence.
34. Brophy JM, Joseph L. Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes. JAMA. 1995;273:871–5. [PubMed] 35. Klevit HD, Bates AC, Castanares T, Kirk EP, Sipes-Metzler PR, Wopat R. Prioritization of health care services. A progress report by the Oregon Health Services Commission. Arch Intern Med. 1991;151:912–6. [PubMed]
36. Banta HD, Luce BR. Oxford, U.K.: Oxford Medical Publications; 1993. Health Care Technology and Its Assessment.
37. Office of Technology Assessment (OTA), U.S. Congress. Identifying Health Technologies That Work: Searching for Evidence. OTA-H-608 Washington, DC: U.S. Government Printing Office; 1994; Five Background Papers. BP-H-142. Washington, DC: U.S. Government Printing Office; 1995.
38. Phelps CE, Mushlin AI. Focusing technology assessment using medical decision theory. Med Decis Making. 1988;8:279–89. [PubMed]
39. Raiffa H. Reading, Mass: Addison-Wesley Publishing Co.; 1968. Decision Analysis: Introductory Lectures on Choices Under Uncertainty.
40. Weinstein MC, Fineberg HV, Frazier AS, Neuhauser D, Neutra RR, McNeil BJ. Philadelphia, Pa: W.B. Saunders Co.; 1980. Clinical Decision Analysis.
41. Sox H, Blatt MA, Higgins MC, Marton KI. Boston, Mass: Butterworths; 1988. Medical Decision Making.
42. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;271:375–81. [PubMed] 43. Willems JS, Sanders CR, Riddiough MA, Bell JC. Cost-effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med. 1980;303:553–9. [PubMed] 44. Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost-effectiveness and public policy. JAMA. 1983;249:3189–95. [PubMed] 45. Mandelblatt JS, Wheat ME, Monane M, Moshief R, Hollenberg J, Tang J. Breast cancer screening for elderly women with and without co-morbid conditions: a decision model. Ann Intern Med. 1992;116:722–30. [PubMed] 46. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419–58. [PubMed] 47. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the coronary heart disease policy model. Am J Public Health. 1987;77:1417–26. [PubMed] 48. Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina. Ann Intern Med. 1990;113:852–71. [PubMed] 49. Eddy DM. Screening for breast cancer. Ann Intern Med. 1989;111:389–99. [PubMed] 50. Fahs M, Mandelblatt JS, Schechter C, Muller C. The costs and effectiveness of cervical cancer screening in the elderly. Ann Intern Med. 1992;117:520–7. [PubMed] 51. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: a decision analytic view. JAMA. 1994;272:773–80. [PubMed] 52. Tosteson AN, Rosenthal DI, Melton L j MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med. 1990;113:594–603. [PubMed] 53. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322–38. [PubMed] 54. Paltiel AD, Kaplan EH. Modeling zidovudine therapy: a cost-effectiveness analysis. J Acquir Immune Defic Syndr. 1991;4:795–804. [PubMed] 55. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418–24. [PubMed]
56. Eddy DM. Cancer Control Objectives for the Nation: 1985–2000. In: Greenwald PG, Sondik EJ, editors. Bethesda, Md: National Institutes of Health; 1986. A computer-based model for designing cancer control strategies. NIH publication no. 86-2880, no. 2. In. eds.
57. Habbema JDF, van Oortmarssen GJ, Lubbe J thn PJ. The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed. 1984;20:79–93. [PubMed] 58. Feuer EJ, Wun LM. How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach. Am J Epidemiol. 1992;136:1423–36. [PubMed]
59. Chang P. A simulation study of breast cancer epidemiology and detection since 1982: the case for limited malignant potential lesions. 1993. PhD dissertation. Department of Industrial Engineering, University of Wisconsin–Madison.
60. Eddy DM. Englewood Cliffs, NJ: Prentice-Hall; 1980. Screening for Cancer: Theory, Analysis and Design.
61. Eddy DM. Screening for cervical cancer. Ann Intern Med. 1990;113:214–6. [PubMed] 62. Eddy DM. Screening for colorectal cancer. Ann Intern Med. 1990;113:373–84. [PubMed] 63. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the “DEALE”), II: use in medical decision-making. Am J Med. 1982;73:889–97. [PubMed] 64. Keeler E, Bell R. New DEALEs: other approximations of life expectancy. Med Decis Making. 1992;12:307–11. [PubMed]
65. Weinstein MC, Stason WB. Cambridge, Mass: Harvard University Press; 1976. Hypertension: A Policy Perspective.
66. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145–51. [PubMed] 67. Oster G, Epstein AM. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. JAMA. 1987;258:2381–7. [PubMed] 68. Psaty BM, Koepsell TD, Manolio TA, et al. Risk ratios and risk differences in estimating the effect of risk factors for cardiovascular disease in the elderly. J Clin Epidemiol. 1990;43:961–70. [PubMed] 69. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301:309–14. [PMC free article] [PubMed] 70. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II) JAMA. 1993;269:3015–23. [PubMed] 71. Brown ML, Brauner C, Minnotte MC. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst. 1993;85:979–87. [PubMed] 72. Greenfield S, Aronow HU, Elashoff RM, Watanabe D. Flaws in mortality data: the hazards of ignoring co-morbid disease. JAMA. 1988;260:2253–5. [PubMed] 73. Prorok PC, Hankey BF, Bundy BN. Concepts and problems in the evaluation of screening programs. J Chron Dis. 1981;34:159–71. [PubMed]
74. Morrison AS. 2d ed. New York, NY: Oxford University Press; 1992. Screening in Chronic Disease.
75. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993;328:1237–43. [PubMed]
76. Shwartz M. A mathematical model used to analyze breast cancer screening strategies. Operation Res. 1978;26:937–55.
77. Shwartz M. Validation and use of a mathematical model to estimate the benefits of screening younger women for breast cancer. Cancer Detect Prev. 1981;4:595–601. [PubMed] 78. van Oortmarssen GJ, Habbema JD, van der Maas PJ, et al. A model for breast cancer screening. Cancer. 1990;66:1601–12. [PubMed] 79. Black WC, Welch HG. A Markov model of early diagnosis. Acad Radiol. 1996;3:S10–12. [PubMed] 80. Eddy DM. The frequency of cervical cancer screening: comparison of a mathematical model with empirical data. Cancer. 1987;60:1117–22. [PubMed] 81. Drummond MF, Davies L. Economic evaluation alongside clinical trials. Int J Technol Assess Health Care. 1991;7:561–73. [PubMed]